A Study of Sotorasib in People With Non-Small Cell Lung Cancer

Conditions

• Non Small Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Sotorasib — DRUG
  Sotorasib 960 mg (8 pills) daily

Study Details

The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)

Key Dates

Start date

Aug 30, 2024

Status verified

Mar 2026

Primary completion

Aug 31, 2026

Completion

Aug 31, 2026

Study Design

Enrollment

39 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Sotorasib
  All patients will start at sotorasib 960 mg (8 pills) daily within 7 days of completion of the pretreatment tumor biopsy.

Primary Outcome Measure

Response to therapy [ Time Frame: within 6 month of therapy ]

Central Contacts

• Gregory Riely, MD, PhD
  646-608-3913
  [email protected]
• Kathryn Arbour, MD
  646-608-3792

Locations (7)

Find similar trials in Basking Ridge, NJ